https://www.selleckchem.com/pr....oducts/pf-07321332.h
AIMS Sodium-glucose cotransporter-2 inhibitors (gliflozins) and statins are oral drugs that may have beneficial cardiovascular effects in patients with type 2 diabetes, especially in those with known cardiovascular disease. We planned a systematic review and meta-analysis of cardiovascular outcome trials (CVOTs) that evaluated the effect of gliflozins on MACE risk in patients with T2D stratified by age and by statin use. METHODS The electronic search was carried out until 20 January 2020. RCTs were included if they were CVOTs perfor